๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · China

Advanced Solid Tumors Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.9 Suzhou Suncadia Biopharmaceuticals Co., Ltd.7 Jiangsu HengRui Medicine Co., Ltd.6 Shanghai Hengrui Pharmaceutical Co., Ltd.6 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.5
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Advanced Solid Tumors trials in China

183 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
NCT07774611Advanced Solid Tumors
DrugBevacizumab
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Not yet open
Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors
NCT07750132Advanced Solid Tumors
Beijing StarMab Biomed Technology Ltd
Phase 1
72
Beijing
2026-09-20
Recruiting
A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors
NCT07719920Advanced Solid Tumors
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
99
Shanghai
2026-09-10
Recruiting
SKB565 for Injection in Advanced Solid Tumors
NCT07545265Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
180
Guangzhou
2026-08-31
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors
NCT07650825Advanced Solid Tumors
DrugsOVV-01·Ivonescimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
30
Hebei
2026-08-01
Recruiting
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
NCT07700160Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
230
Beijing, Shanghai, Hangzhou
2026-07-30
Recruiting
A Phase I Study of CS5007 in Participants With Advanced Solid Tumors
NCT07622524Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1
310
Shanghai
2026-07-16
Not yet open
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
NCT07699757Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
DrugsHSK41959·Cisplatin/carboplatin·Sintilimab·Nab-paclitaxel
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
258
Shanghai
2026-07
Not yet open
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
NCT07624214Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase 1
198
Hangzhou
2026-07
Not yet open
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors
NCT07738679Advanced Solid Tumors
DrugTQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Not yet open
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
NCT07601334Advanced Solid Tumors
DrugHF50
HighField Biopharmaceuticals Corporation
Phase 1
45
Guangzhou
2026-06-30
Recruiting
Allogeneic WTX-212C in Advanced Solid Tumors
NCT07556653Advanced Solid Tumors
Zhejiang Provincial People's Hospital
Phase EARLY_PHASE1
24
Hangzhou
2026-06-26
Not yet open
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
NCT07504445Advanced Solid Tumors
Peking University Shenzhen Hospital
Phase EARLY_PHASE1
10
Shenzhen
2026-06-10
Recruiting
SKB118 Injection in Advanced Solid Tumors
NCT07586943Advanced Solid Tumors
DrugsSKB118·Sacituzumab tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
530
Shanghai
2026-06-01
Not yet open
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
NCT07615894Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
WestVac Biopharma Co., Ltd.
Phase 1
9
Chengdu
2026-06-01
Not yet open
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
NCT07412665Advanced Solid Tumors
DrugGK01
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1
10
Beijing
2026-06
Not yet open
A Phase โ…  Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1
186
Shanghai
2026-06
Not yet open
FAK Inhibitor in Patients With Advanced Solid Tumors
NCT07596381Advanced Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1
75
Hangzhou
2026-05-30
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors
NCT07563972Advanced Solid Tumors, Neoplasm
West China Hospital
Phase 1
9
Chengdu
2026-05-10
Recruiting
SKB103 for Injection in Advanced Solid Tumors
NCT07459998Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
277
Harbin, Shanghai
2026-04-23
Recruiting
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
NCT07648472Advanced Solid Tumors
DrugOVV-01
Joint Biosciences Ltd.
Phase 1
18
Beijing
2026-04-21
Recruiting
A Study of HDM2024 in Participants With Advanced Solid Tumors
NCT07539285Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
63
Shanghai
2026-04-10
Recruiting
HWS116 Monotherapy in Patients With Advanced Solid Tumors
NCT07413328Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1
56
Guangzhou
2026-04-07
Not yet open
Safety, Tolerability, and Preliminary Efficacy of Peginterferon ฮฑ-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors
NCT07438093Advanced Solid Tumors
DrugPeginterferon ฮฑ-2b
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2026-04
Not yet open
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
NCT07482319Advanced Solid Tumors
DrugGK01
Beijing Geekgene Technology Co., LTD
Phase 1
15
Beijing
2026-04
Active, closed
Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection
NCT07826585Advanced Solid Tumors
Corregene Biotechnology Co., Ltd
Phase 1
6
Beijing
2026-03-26
Recruiting
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT07561437Advanced Solid Tumors
DrugNK521 Cell
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Beijing
2026-03-09
Recruiting
SKB105 for Injection in Advanced Solid Tumors
NCT07380386Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
256
Beijing, Shanghai
2026-03-05
Recruiting
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
NCT07589530Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
DrugFludarabine
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
NCT07414316Advanced Solid Tumors
DrugGK01
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1
10
Nanchang
2026-02-13
Not yet open
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
NCT07327294Advanced Solid Tumors
Evopoint Biosciences Inc.
Phase 1/2
150
Guangzhou
2026-01-31
Recruiting
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
NCT07328217Advanced Solid Tumors
DrugGW5282
Dizal Pharmaceuticals
Phase 1/2
203
Beijing
2026-01-29
Recruiting
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
120
Hangzhou
2026-01-29
Recruiting
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
NCT07222969Advanced Solid Tumors
Vibrant Sciences Limited
Phase 1/2
146
Guangzhou
2026-01-12
Recruiting
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
NCT07349160Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2026-01-10
Recruiting
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
NCT07131202Advanced Solid Tumors
DrugsFL115·PD-1
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
130
Guangzhou
2026-01-08
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
NCT07359066Advanced Solid Tumors, PARP Inhibitor
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Beijing, Harbin
2026-01-08
Recruiting
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
NCT07321574SCLC, Extensive Stage, Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
NCT07310134Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1
80
Shanghai
2025-12-26
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
NCT07596693Advanced Solid Tumors
DrugKXV01 TCR Lentinvivo
TCRx Therapeutics Co.Ltd
Phase 1
30
Shanghai
2025-12-19
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
NCT07251166Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
170
Shenyang
2025-12-10
Recruiting
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
NCT07446816Advanced Solid Tumors
DrugHemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
24
Xinxiang
2025-12-03
Not yet open
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
NCT07275853Advanced Solid Tumors
DrugKXV01 TCR Lentinvivo
TCRx Therapeutics Co.Ltd
Phase 1
30
Beijing
2025-12-01
Recruiting
FL-261 Imaging for Cancer Diagnosis and Staging
NCT07510321Non-Small Cell Lung Cancer, Colorectal Cancer, Head & Neck Cancer, Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
12
Wuhan
2025-11-27
Recruiting
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
NCT07253116Advanced Solid Tumors
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2
20
Beijing
2025-11-20
Recruiting
GenSci139 in Patients With Advanced Solid Tumors
NCT07230977Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
280
Jinan
2025-11-19
Recruiting
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
NCT07702162Advanced Solid Tumors, Cancer
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
49
Fuzhou, Shanghai
2025-11-14
Recruiting
HS-20117-2 Injection in Patients With Advanced Solid Tumors
NCT07775703Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1
60
Guangzhou
2025-11-13
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
NCT07241936Advanced Solid Tumors
DrugsDP303c·SYS6043·SYS6010·Sirolimus
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
444
Shanghai
2025-11-13
Recruiting
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
NCT07285395Advanced Solid Tumors
DrugSBRT
The Affiliated Hospital of Xuzhou Medical University
Phase 1
12
Xuzhou
2025-11-12
Recruiting
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
NCT06144671Advanced Solid Tumors
DrugsGT201·Aldesleukin
Grit Biotechnology
Phase 1/2
78
Shanghai, Chengdu
2025-11-01
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsSerplulimab·Ivonescimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Recruiting
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
NCT07208136Advanced Solid Tumors
Jemincare
Phase 1
102
Beijing
2025-10-22
Not yet open
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
NCT07207681Advanced Solid Tumors
DrugKXV01 TCR Lentinvivo
The First Hospital of Jilin University
Phase 1
30
Changchun
2025-10-15
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
DrugBMS-986504
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Not yet open
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787Advanced Solid Tumors
DrugsIMM01·IMM2510
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2
104
Shanghai
2025-10-15
Recruiting
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
NCT07186452Advanced Solid Tumors
DrugsHS-20093·Itraconazole
Hansoh BioMedical R&D Company
Phase 1
18
Changsha
2025-09-23
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
DrugsFurmonertinib Mesilate·YL202·Toripalimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
NCT07164950Urothelial Carcinoma, Advanced Solid Tumors, Chemotherapy-Induced Peripheral Neuropathy, Antibody-drug Conjugates
Sheng Zhang
Not applicable
58
Shanghai
2025-08-30
Recruiting
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
NCT07106814Advanced Solid Tumors
Anhui Provincial Hospital
Phase EARLY_PHASE1
36
Hefei
2025-08-29
Active, closed
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
NCT07122063Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
266
Shenyang
2025-08-11
Recruiting
A Study of AK146D1 for Injection in Advanced Solid Tumors
NCT07067567Advanced Solid Tumors
DrugAK146D1
Akeso
Phase 1
200
Guangzhou
2025-08-07
Recruiting
A Study of HDM2012 in Patients With Advanced Solid Tumor
NCT07100249Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
129
Shanghai
2025-08-06
Recruiting
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
NCT07060989Advanced Solid Tumors
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Shanghai
2025-08-04
Not yet open
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
NCT07101549Advanced Solid Tumors
changjianhua
Phase 1
25
Shenzhen
2025-08-01
Not yet open
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
NCT07136558Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
410
Guangzhou
2025-08
Not yet open
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
NCT06998173Advanced Solid Tumors
Danatlas Pharmaceuticals Co., Ltd
Phase 1
228
Beijing
2025-07-31
Not yet open
A Study of QLS5133 Monotherapy in Advanced Solid Tumors
NCT07061639Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
212
Shanghai
2025-07
Recruiting
Study of CM518D1 in Patients With Advanced Solid Tumors
NCT07019779Advanced Solid Tumors
Keymed Biosciences Co.Ltd
Phase 1/2
434
Guangzhou
2025-06-27
Recruiting
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
NCT07185243Advanced Solid Tumors
Hangzhou Converd Co., Ltd.
Not applicable
24
Xiamen
2025-06-23
Recruiting
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
NCT06993870Advanced Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2025-06-16
Recruiting
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
NCT06990698Advanced Solid Tumors
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Wuhan, Taiyuan, Hangzhou
2025-06-12
Recruiting
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
NCT06990464Advanced Solid Tumors
Shanghai Institute Of Biological Products
Phase 1
156
Fuzhou
2025-06-11
Recruiting
HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
NCT06822998Advanced Solid Tumors
DrugHF50
HighField Biopharmaceuticals Corporation
Phase EARLY_PHASE1
10
Chengdu
2025-06-11
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Not yet open
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
NCT06963502Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
DrugsPlatinum (cisplatin·HS-10370·HS-20117·HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
762
Hangzhou, Shanghai
2025-05-30
Recruiting
A Study of HDM2005 in Patients With Advanced Solid Tumor
NCT07004296Advanced Solid Tumors
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
72
Shanghai
2025-05-29
Recruiting
HW071021 Monotherapy in Patients With Advanced Solid Tumors
NCT06882135Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1
76
Guangzhou
2025-05-28
Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
DrugsAK129·Cis-platinum·Penpulimab·5-FU
Akeso
Phase 1/2
230
Shenyang
2025-05-21
Recruiting
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
NCT06840821Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2
156
Jinan
2025-05-08
Not yet open
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors
NCT06932094Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1
256
Hangzhou
2025-05
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2
130
Chongqing, Jinan, Shanghai
2025-04-30
Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
A Study of HS-20122 in Patients With Advanced Solid Tumors
NCT06927570Advanced Solid Tumors
DrugHS-20122
Hansoh BioMedical R&D Company
Phase 1
1,050
Guangzhou
2025-04-15
Recruiting
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
NCT06968572Advanced Solid Tumors
DrugHSK41959
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
245
Guiyang, Nanjing, Shanghai
2025-04-11
Recruiting
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
NCT06907628Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
150
Jinan
2025-04-02
Not yet open
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
NCT06906731Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
27
Harbin
2025-04
Recruiting
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
NCT07744763Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
260
Shanghai
2025-03-28
Recruiting
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NCT06895928Advanced Solid Tumors
DrugsAmetinib Mesylate·SHR-A2102·Osimertinib·Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
400
Taiyuan
2025-03-28
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
NCT06954558Advanced Solid Tumors
DrugGK01
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-03-18
Not yet open
Allogeneic B7H3 CAR-ฮณฮดT Cell Therapy for Advanced Solid Tumors
NCT06825455Advanced Solid Tumors, Ovarian Cancers, Peritoneal (metastatic) Cancer
DrugsFludarabine·Cyclophosphamide
Peking University
Phase EARLY_PHASE1
18
Beijing
2025-03-01
Not yet open
Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System
NCT06824792Advanced Solid Tumors
NING LI
Phase 4
3,000
Langfang
2025-03-01
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
Drugs5-FU·Leucovorin·Irinotecan·Etoposide
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
NCT06703177Advanced Solid Tumors
DrugsSHR-1826·SHR-9839·Calcium folinate·SHR-8068
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
876
Guangzhou
2025-02-18
Rows per page Showing 1–100 of 183
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumors

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 183 of those studies listing the condition Advanced Solid Tumors.

How many Advanced Solid Tumors trials are recruiting in China?

132 of the 183 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 35 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumors), 183 studies
PhaseStudiesRecruitingShare
Phase 1996754.1%
Phase 1/2584831.7%
Phase EARLY_PHASE11286.6%
Phase 2854.4%
Not applicable321.6%
Observational221.1%
Phase 4100.5%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumors)
Lead sponsorStudiesRecruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.99
Suzhou Suncadia Biopharmaceuticals Co., Ltd.76
Jiangsu HengRui Medicine Co., Ltd.64
Shanghai Hengrui Pharmaceutical Co., Ltd.65
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.55
MediLink Therapeutics (Suzhou) Co., Ltd.54
Hansoh BioMedical R&D Company44
Akeso32
Bayer31
Beijing Geekgene Technology Co., LTD31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.